Ben Greenblum has extensive experience in antitrust and other complex civil litigation. Ben joined the firm in 2007, and joined the firm’s Executive Committee in January 2025.
Ben specializes in defending antitrust litigation brought by government enforcers, competitors, purchasers, and class action plaintiffs. Ben is recognized as a leading member of the bar defending so-called “pay for delay” patent settlements from antitrust attack, serving as trial counsel in the first two such cases ever to go to jury verdict. Ben has defended clients against claims of sham litigation and Walker Process fraud, and has also served as lead counsel in affirmative patent infringement claims. With years of experience litigating such cases, Ben advises on all manner of antitrust issues arising from Hatch-Waxman and BPCIA litigation.
Ben also served on the trial team in the monopolization case brought against Google by the Department of Justice relating to Google Search.
In 2022-2025, Chambers USA recognized Ben as an “Antitrust: Litigation Specialist” in the District of Columbia, describing him as a “highly strategic and effective litigator with a deep knowledge of pharmaceutical antitrust issues.” Ben was also recognized in 2022 as a BTI Client Service All-Star for “how quickly [he] assesses a situation and then assembles the absolute best team for the job.” The 2021 edition of The Legal 500 described Ben as an “excellent trial lawyer and legal writer” who is “very accessible to his clients and always provides sound and strategic counseling.” And Lawdragon has named Ben among the “500 Leading Litigators in America” since 2023. That same year, The American Lawyer recognized Ben as a “Litigator of the Week Runner Up” for successfully representing Norton (Waterford) Ltd. and Teva Branded Pharmaceutical Products as lead trial counsel in patent litigation concerning their Qvar asthma inhaler, in which the Court ruled for them on every issue.
Ben was part of the trial team that defended a pharmaceutical company from a multi-billion antitrust claim challenging an alleged “reverse payment” patent settlement in the District of Massachusetts. The 2014 jury verdict for the defense was affirmed on appeal. Since then, Ben has represented several pharmaceutical companies in various high-stakes antitrust disputes, including on novel theories of refusal to deal. In 2022, Ben was part of the trial team that defended a pharmaceutical company from a different multi-billion antitrust claim in the Northern District of Illinois; the jury verdict was for the defense. And in 2024, Ben won dismissal of two separate sham litigation complaints brought against his clients.
Ben also has experience in a range of other substantive areas, including unfair competition and licensing disputes. He has represented several Fortune 500 companies in contract, licensing, and other disputes related to their intellectual property.
A native of Washington, D.C., Ben graduated summa cum laude from the University of Pennsylvania in 2001, earning both a B.S. from the Wharton School and a B.A. from the College of Arts & Sciences. He then graduated at the top of his class in Columbia Law School in 2006, earning the James Kent Scholar designation each year.
Ben joined the firm in 2007 after clerking for the Honorable Dennis Jacobs, then-Chief Judge of the United States Court of Appeals for the Second Circuit. He currently serves as the Vice Chair of the firm’s Budget Committee.
Representative Experience
Though all cases vary and none is predictive, Ben’s experience also includes:
- Defense counsel in several antitrust litigations brought against the high-tech industry, alleging monopolization and restraints of trade.
- Lead trial counsel in a Hatch-Waxman infringement action, winning an injunction for patentee on all asserted claims.
- Defense counsel in federal district court proceedings brought by competitors and purchasers alleging monopolization by means of alleged refusals to deal, sham litigation, improper Orange Book listings, and unlawful settlements.
- Defense counsel to food manufacturers in antitrust and unfair competition cases alleging price-fixing, anticompetitive distribution restrictions and mislabeling.
- Lead defense counsel for distributor in MDL antitrust proceeding in concerning alleged antitrust conspiracy.
- Plaintiff counsel in licensing and contract disputes related to first-of-its kind antibody product.
- Defense counsel and witness counsel in multiple FTC investigations.